JacquelineVukyMD

Oncology • Portland, OR

Genitourinary Oncology

Associate Professor, Division Hematology-Oncology, Oregon Health and Science University School of Medicine

Join to view full profile

Dr. Vuky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Vuky's full profile

Already have an account?

Office
3485 S. Bond Avenue
OCP14P
Portland, OR 97239
Phone+1 503-494-1091

Fax+1 503-494-6197
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1995 - 1998
Oregon Health and Science University School of MedicineClass of 1995

Certifications & Licensure

MT State Medical License 2022 - 2026
OR State Medical License 2011 - 2025
WA State Medical License 2001 - 2012
NY State Medical License 1996 - 2002
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
Completed
Phase 3
Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer Start of enrollment: 2003 May 01
Completed
Phase 2
Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer Start of enrollment: 2006 Apr 01
Unknown status
Phase 2
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 2
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
Active, not recruiting
Phase 3
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer Start of enrollment: 2008 Apr 23
Completed
Phase 2
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Start of enrollment: 2010 Dec 01
Completed
Phase 3
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance Start of enrollment: 2011 Jan 01
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer Start of enrollment: 2012 May 16
Completed
Not Applicable
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Start of enrollment: 2018 Oct 31
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
Active, not recruiting
Phase 3
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer Start of enrollment: 2019 Dec 10
Active, not recruiting
Phase 1
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Start of enrollment: 2020 Aug 13
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Pacli...
Douglas M Dahl, Theodore G Karrison, M Dror Michaelson, Huong T Pham, Chin-Lee Wu, Gregory P Swanson, William U Shipley, Jacqueline Vuky, R Jeffrey Lee, Anthony L Ziet...> ;European Urology Oncology. 2024 Feb 1
20 citations
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
A V Balar, D E Castellano, P Grivas, D J Vaughn, T Powles, J Vuky, Y Fradet, J-L Lee, L Fong, N J Vogelzang, M A Climent, A Necchi, D P Petrylak, E R Plimack, J Z Xu, ...> ;Annals of Oncology. 2023 Mar 1
11 citations
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a...
John Hilton, Mihaela Cristea, Sophie Postel-Vinay, Capucine Baldini, Mark Voskoboynik, William Edenfield, Geoffrey I Shapiro, Michael L Cheng, Jacqueline Vuky, Bradley...> ;Cancers. 2022 Aug 23
73 citations
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Vivek Subbiah, Philippe A Cassier, Salvatore Siena, Elena Garralda, Luis Paz-Ares, Pilar Garrido, Ernest Nadal, Jacqueline Vuky, Gilberto Lopes, Gregory P Kalemkerian,...> ;Nature Medicine. 2022 Aug 1
16 citations
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A Climent, Daniel P Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N Sternberg, Peter H O'Donnell, Tho...> ;Clinical Cancer Research. 2022 May 13
8 citations
Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.
Marilyne Labrie, Allen G. Li, Allison L. Creason, Courtney Betts, Jamie M. Keck, Brett Johnson, Shamilene Sivagnanam, Christopher Boniface, Hongli Ma, Aurora Blucher, ...> ;NPJ Precision Oncology. 2021 Oct 19
4 citations
Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future Outlook.
Zizhen Feng, Jacqueline Vuky> ;Oncology. 2021 Jul 15
259 citations
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, ...
Thomas Powles, Tibor Csőszi, Mustafa Ozguroglu, Nobuaki Matsubara, Lajos Géczi, Susanna Y-S Cheng, Yves Fradet, Stéphane Oudard, Christof Vulsteke, Rafael Morales Barr...> ;The Lancet. Oncology. 2021 Jul 1
136 citations
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelia...
Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano, Peter H. O'Donnell, Petros Grivas, Joaquim Bellmunt, Thomas Powles, Dean F. Bajorin, Noah M. Hahn, Mary J. Sava...> ;Journal of Clinical Oncology. 2020 Jun 17
26 citations
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
Petros Grivas, Elizabeth R. Plimack, Arjun Vasant Balar, Daniel Castellano, Peter H. O'Donnell, Joaquim Bellmunt, Thomas Powles, Noah M. Hahn, Ronald de Wit, Dean F. B...> ;European Urology Oncology. 2020 Jun 1
832 citations
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-a...
Arjun Vasant Balar, Daniel Castellano, Peter H. O'Donnell, Petros Grivas, Jacqueline Vuky, Thomas Powles, Elizabeth R. Plimack, Noah M. Hahn, Ronald de Wit, Lei Pang, ...> ;The Lancet. Oncology. 2017 Nov 1
35 citations
A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Nonc...
M. Dror Michaelson, Chen Hu, Huong T. Pham, Douglas M. Dahl, Chin Lee-Wu, Gregory P. Swanson, Jacqueline Vuky, R. Jeffrey Lee, Luis Souhami, Brian S. Chang, Asha Georg...> ;International Journal of Radiation Oncology, Biology, Physics. 2017 Apr 1
30 citations
Randomized Trial to Assess the Impact of Venlafaxine and Soy Protein on Hot Flashes and Quality of Life in Men With Prostate Cancer
Mara Z. Vitolins, Leah Griffin, W. Vic Tomlinson, Jacqueline Vuky, Paul T. Adams, Dawn B Moose, Bart Frizzell, Glenn J. Lesser, Michelle J. Naughton, James E. Radford,...> ;Journal of Clinical Oncology. 2013 Nov 10
19 citations
Phase II Trial of Neoadjuvant Docetaxel and CG1940/CG8711 Followed by Radical Prostatectomy in Patients With High-Risk Clinically Localized Prostate Cancer
Jacqueline Vuky, John M. Corman, Christopher R. Porter, Semra Olgac, Evan Auerbach, Kathryn Dahl> ;The Oncologist. 2013 Jun 1
30 citations
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer
Robert Jones, Jacqueline Vuky, Tony Elliott, Graham M. Mead, Jose Angel Arranz, John D. Chester, Simon Chowdhury, Arkadiusz Z. Dudek, Volker Müller-Mattheis, Marc-Oliv...> ;Investigational New Drugs. 2013 Jan 18
18 citations
Phase II Study of Long-Term Androgen Suppression With Bevacizumab and Intensity-Modulated Radiation Therapy (IMRT) in High-Risk Prostate Cancer
Jacqueline Vuky, Huong T. Pham, Sarah Warren, Erika Douglass, K. Badiozamani, Berit Madsen, Alex Hsi, G. Song> ;International Journal of Radiation Oncology, Biology, Physics. 2012 Mar 15
46 citations
A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7.
Sandhya Pruthi, R. Qin, Shelby A. Terstreip, Heshan Liu, Charles L. Loprinzi, Tushar R.C. Shah, Kenneth F. Tucker, Shaker R. Dakhil, Martin J. Bury, Robert L. Carolla,...> ;Menopause. 2012 Jan 1
50 citations
Combined weekly topotecan and biweekly bevacizumab in women with platinum‐resistant ovarian, peritoneal, or fallopian tube cancer
Kathryn F. McGonigle, Howard G. Muntz, Jacqueline Vuky, Pamela J. Paley, Dan S. Veljovich, Benjamin E. Greer, Barbara A. Goff, Heidi J. Gray, T. W. Malpass> ;Cancer. 2011 Aug 15
The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7.
Pruthi S, Qin R, Terstriep SA, Liu H, Loprinzi CL, Shah TRC, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL> ;J. Clin. Oncol.. 2011-06-20
Phase III randomized, double-blind, placebo-controlled trial of soy protein and venlafaxine for treatment of hot flashes in men with prostate cancer.
Vitolins M, Griffin L, Tomlinson WV, Vuky J, Fried DB, Adams PT, Moose D, Frizzell B, Radford JE, Shah TRC, Shaw EG> ;J. Clin. Oncol.. 2011-05-20
The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7.
Pruthi S, Qin R, Terstriep SA, Liu H, Loprinzi CL, Shah TRC, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL> ;J. Clin. Oncol.. 2011-05-20
8 citations
A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma.
Christopher W. Ryan, Jacqueline Vuky, Joseph S. Chan, Zunqiu Chen, Tomasz M. Beer, Deirdre Nauman> ;Investigational New Drugs. 2011 Apr 1
Phase II study of everolimus (E) with imatinib (IM) in patients with previously-treated renal carcinoma (RCC).
Ryan CW, Vuky J, Chan JS, Beer TM, Rothkopf M> ;J. Clin. Oncol.. 2009-05-20
36 citations
Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
Jacqueline Vuky, Christopher R. Porter, Christina Isacson, Matthew Vaughan, Paul M. Kozlowski, Vincent J. Picozzi, John M. Corman> ;Cancer. 2009 Feb 15
A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk ...
Hidalgo M, Tirado Gomez M, Lewis N, Vuky JL, Taylor G, Hayburn JL, Hsu K, Kosh M, Picozzi VJ> ;J. Clin. Oncol.. 2008-05-20
Join now to see all

Lectures

Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial canc...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018